Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A pharmaceutical composition containing tepagliflozin for treating diabetic cardiomyopathy

A technology of diabetic cardiomyopathy and composition, which is applied in the field of medicine, can solve the problems of undiscovered tepagliflozin, toxic and side effects, etc., achieve the effect of low drug toxic and side effects, reduce toxic and side effects, and enhance the therapeutic effect

Active Publication Date: 2022-05-06
GUANGZHOU LIXIN PHARM CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, most of the drugs for the treatment of diabetic cardiomyopathy are hypoglycemic drugs such as metformin, thiazolidinediones (insulin sensitizers), natural glucagon-like peptide-1, and dipeptidyl peptidase-4. There are certain toxic and side effects and use restrictions in the treatment of diabetic cardiomyopathy, so it is very urgent to continue research to find a drug that can effectively treat diabetic cardiomyopathy. For the treatment of diabetic cardiomyopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition containing tepagliflozin for treating diabetic cardiomyopathy
  • A pharmaceutical composition containing tepagliflozin for treating diabetic cardiomyopathy
  • A pharmaceutical composition containing tepagliflozin for treating diabetic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1. The pharmaceutical composition of the present invention for the treatment of diabetic cardiomyopathy

[0023] It is made up of a mixture of Tagagliflozin 10g and Pravastatin 15g.

Embodiment 2

[0024] Embodiment 2. The pharmaceutical composition of the present invention for the treatment of diabetic cardiomyopathy

[0025] It is made up of a mixture of Tagagliflozin 5g and Pravastatin 20g.

Embodiment 3

[0026] Embodiment 3. The pharmaceutical composition of the present invention for the treatment of diabetic cardiomyopathy

[0027] It is made up of a mixture of Tagagliflozin 7g and Pravastatin 18g.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, and specifically discloses a pharmaceutical composition containing tepagliflozin for treating diabetic cardiomyopathy. The pharmaceutical composition includes tepagliflozin and statin lipid-lowering drugs, and the statin lipid-lowering drugs include lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, rosu One of Vastatin and Pitavastatin. Through the synergistic effect of tepagliflozin and statins, the blood sugar concentration of diabetic patients can be effectively controlled, and at the same time, it has a certain effect on the treatment of myocardial dysfunction caused by diabetes complications. safe and effective.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition containing tagagliflozin for treating diabetic cardiomyopathy. Background technique [0002] With the rapid development of social economy and the continuous improvement of people's living standards, the prevalence of diabetes among adults in my country has increased significantly, from 0.67% in 1980 to 10.4% in 2013. According to the 8th edition of the Global Diabetes Map released by the International Diabetes Federation (IDF) in 2017, the prevalence of diabetes in China was 10.9% in 2017, and the number of diabetic patients reached 114 million, accounting for 25% of the world's total adult diabetic patients. Above, ranking first in the world, this figure is still growing and is expected to increase to 120 million by 2045. Therefore, the prevention and treatment of diabetes is particularly important. At present, the treatment strategy o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/351A61K45/06A61K31/366A61K31/22A61K31/405A61K31/40A61K31/505A61K31/47A61K31/4709A61P3/10A61P9/00
CPCA61K31/351A61K45/06A61K31/366A61K31/22A61K31/405A61K31/40A61K31/505A61K31/47A61K31/4709A61P3/10A61P9/00A61K2300/00
Inventor 高悦译刘恩桂张倩卢江
Owner GUANGZHOU LIXIN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com